{"doi":"10.1016/j.esmoop.2023.101832","title":"Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?","abstract":null,"journal":"ESMO Open","year":2023,"id":633847,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1546663,"name":"B. Pistilli","orcid":null,"position":1,"is_corresponding":false},{"id":1643570,"name":"T. Grinda","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?","abstract":"Are ERBB2 mutations a 'ready for routine use' target in patients with","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37769401","pmcid":"PMC10539925","openalex_id":"https://openalex.org/W4387037271","authors":[],"funders":[],"total_grants":0,"fwci":0.1872,"citation_percentile":0.46659148,"influential_citations":0,"citation_trend":[{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1016/j.esmoop.2023.101832","host_type":"journal"},{"url":"https://doi.org/10.1016/j.esmoop.2023.101832","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2059702923010670?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2059702923010670?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37769401","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10539925","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10539925/pdf/main.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC10539925","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10539925?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Ubiquitin and proteasome pathways","Cancer-related Molecular Pathways","Peptidase Inhibition and Analysis"],"mesh_terms":[],"keywords":["Metastatic breast cancer","Breast cancer","Oncology","Medicine","Cancer","Internal medicine"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T12:46:23.101447Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}